Use of selective Beta-3 adrenergic receptor agonists to treat pulmonary hypertension

  • Pulmonary hypertension (PH), defined as the increase of mean pulmonary blood pressure above normal values, encompasses a series of disorders characterized by the increase of pulmonary vascular resistance and progressive deterioration of the right ventricle. The incidence of pulmonary hypertension in the population is high and it is associated with high morbidity and mortality. Approximately two thirds of patients with left ventricular dysfunction (systolic or isolated diastolic) develop pulmonary hypertension. Currently, there is a lack of treatments for pulmonary hypertension.

    CNIC and CLINIC researchers have described a novel effective treatment for pulmonary hypertension of different etiology, both chronic and acute. They have found that selective stimulation of beta-3 adrenergic receptors has a beneficial effect in pulmonary hypertension.

    Number
    EP2891490A1
    Priority date
    29/08/2012
    Applicants
    CNIC, CLINIC
    Inventors
    Borja Ibáñez Cabeza, Valentín Fuster Carulla, Ana García-Álvarez